These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9154441)

  • 1. Commentary: the use of maximum tolerated dose in rodent carcinogenicity bioassays and its relevance to human risk assessment.
    Savolainen K
    Hum Exp Toxicol; 1997 Apr; 16(4):190-2. PubMed ID: 9154441
    [No Abstract]   [Full Text] [Related]  

  • 2. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Principles of risk assessment for determining the safety of chemicals: recent assessment of residual solvents in drugs and di(2-ethylhexyl) phthalate.
    Hasegawa R; Koizumi M; Hirose A
    Congenit Anom (Kyoto); 2004 Jun; 44(2):51-9. PubMed ID: 15198717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mouse carcinogenicity study is no longer a scientifically justifiable core data requirement for the safety assessment of pesticides.
    Billington R; Lewis RW; Mehta JM; Dewhurst I
    Crit Rev Toxicol; 2010 Jan; 40(1):35-49. PubMed ID: 20144135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissecting modes of action of non-genotoxic carcinogens in primary mouse hepatocytes.
    Schaap MM; Zwart EP; Wackers PF; Huijskens I; van de Water B; Breit TM; van Steeg H; Jonker MJ; Luijten M
    Arch Toxicol; 2012 Nov; 86(11):1717-27. PubMed ID: 22710402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo Comet assay on isolated kidney cells to distinguish genotoxic carcinogens from epigenetic carcinogens or cytotoxic compounds.
    Nesslany F; Zennouche N; Simar-Meintières S; Talahari I; Nkili-Mboui EN; Marzin D
    Mutat Res; 2007 Jun; 630(1-2):28-41. PubMed ID: 17507283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995-2009).
    Friedrich A; Olejniczak K
    Regul Toxicol Pharmacol; 2011 Jul; 60(2):225-48. PubMed ID: 21513764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling.
    Valerio LG; Arvidson KB; Chanderbhan RF; Contrera JF
    Toxicol Appl Pharmacol; 2007 Jul; 222(1):1-16. PubMed ID: 17482223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammary gland neoplasia.
    Neumann DA; Crisp TM; Olin SS
    Environ Health Perspect; 1996 Sep; 104(9):912-4. PubMed ID: 8899366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revisiting alternative approaches to the assessment of carcinogenic risk.
    Downes N
    Toxicol Pathol; 2010 Feb; 38(2):324-7. PubMed ID: 20124498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methods.
    Matthews EJ; Kruhlak NL; Cimino MC; Benz RD; Contrera JF
    Regul Toxicol Pharmacol; 2006 Mar; 44(2):97-110. PubMed ID: 16352383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
    Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
    Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human cancer risk estimates are reduced when based on relative risk for common rodent tumors.
    Gaylor DW; Kodell RL; Chen JJ
    Regul Toxicol Pharmacol; 1999 Dec; 30(3):283-4. PubMed ID: 10620477
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of non-mammalian species in bioassays for carcinogenicity.
    Bunton TE
    IARC Sci Publ; 1999; (146):151-84. PubMed ID: 10353387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diet and test animals.
    Bucher JR; Rao GN; Abdo K; Kari F; Lucier G
    Science; 1995 Dec; 270(5241):1421-2. PubMed ID: 7491480
    [No Abstract]   [Full Text] [Related]  

  • 16. An integrated approach for prospectively investigating a mode-of-action for rodent liver effects.
    LeBaron MJ; Geter DR; Rasoulpour RJ; Gollapudi BB; Thomas J; Murray J; Kan HL; Wood AJ; Elcombe C; Vardy A; McEwan J; Terry C; Billington R
    Toxicol Appl Pharmacol; 2013 Jul; 270(2):164-73. PubMed ID: 23607986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes.
    Patlewicz G; Simon TW; Rowlands JC; Budinsky RA; Becker RA
    Regul Toxicol Pharmacol; 2015 Apr; 71(3):463-77. PubMed ID: 25707856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Need for dietary control by caloric restriction in rodent toxicology and carcinogenicity studies.
    Keenan KP; Laroque P; Dixit R
    J Toxicol Environ Health B Crit Rev; 1998; 1(2):135-48. PubMed ID: 9650534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments.
    Butterworth BE; Conolly RB; Morgan KT
    Cancer Lett; 1995 Jun; 93(1):129-46. PubMed ID: 7600540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.
    Battershill JM; Fielder RJ
    Hum Exp Toxicol; 1998 Apr; 17(4):193-205. PubMed ID: 9617631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.